Evaluation of Cerebral Spinal Fluid (CSF) Proteome and Angiogenesis Proteins in Children With Newly Diagnosed Central Nervous System Tumors
- Investigate the feasibility of centrally collecting and processing high-quality
cerebrospinal fluid (CSF) samples from pediatric patients with newly diagnosed central
nervous system tumors for proteomic studies.
- Identify protein markers that might indicate the presence of a brain tumor using CSF
samples collected from these patients.
OUTLINE: This is a multicenter study.
Patients undergo cerebrospinal fluid (CSF) collection from any or all of the following 5
sites: lumbar, cervical, ommaya, intra-operative (ventricular, cisternal), and/or external
ventricular drain. CSF is obtained within 8 weeks of diagnosis but prior to (or concurrent
with) the initiation of any post-operative therapy (excluding corticosteroids).
CSF samples are examined for proteomic biomarkers by 2D gel electrophoresis, low-mass
fingerprinting, and stable isotope labeling.
PROJECTED ACCRUAL: A total of 99 patients will be accrued for this study.
Observational Model: Cohort, Time Perspective: Prospective
Number of IRB approvals of the study
IRB approval will be used as a surrogate marker of support for this protocol.
Within 120 days of study release
Brian R. Rood, MD
Children's Research Institute
United States: Federal Government
|Children's Hospital of Philadelphia||Philadelphia, Pennsylvania 19104|
|Duke Comprehensive Cancer Center||Durham, North Carolina 27710|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Children's National Medical Center||Washington, District of Columbia 20010-2970|
|Children's Hospital of Pittsburgh||Pittsburgh, Pennsylvania 15213|
|Children's Hospital and Regional Medical Center - Seattle||Seattle, Washington 98105|
|Children's Memorial Hospital - Chicago||Chicago, Illinois 60614|
|Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital||Houston, Texas 77030-2399|